The genus Acinetobacter is a heterogeneous group of organisms that comprises 17 named species and 15 species that have no valid names as of yet. Acinetobacter baumannii and the closely related ...

The Swiss drugmaker says the safety and efficacy of zosurabalpin will be investigated in a study involving 400 patients with ...

An experimental antibiotic, zosurabalpin, to fight a deadly superbug has entered the final human trials. Currently, no new ...

Swiss drugmaker Roche said on Monday it would advance testing of an antibiotic against a common drug-resistant bacteria that ...

Australia’s second-largest private hospital operator, Healthscope, is in receivership with ten non-binding offers for ...

Acinetobacter baumannii are bacteria that cause infections in the blood, lungs, kidneys, brain, and other organs. These bacteria are nonmotile (don't move on their own), strictly aerobic (need ...

The bacterium Acinetobacter baumannii is particularly feared, and there is great pressure to devise novel therapeutic approaches to combat it. Bioinformaticians have now detected an unexpectedly ...

The bacteria, Acinetobacter baumannii, can cause serious infections in the lungs, urinary tract and blood, according to the US Centers for Disease Control and Prevention. It’s resistant to a ...

Acinetobacter baumannii has emerged in the last decades as a major cause of healthcare-associated infections and nosocomial outbreaks. Multidrug-resistant (MDR) A. baumannii is a rapidly emerging ...

Hundreds of patients will be recruited for a major trial of what could be the first new antibiotic of its kind for 50 years.

The carbapenem antibiotics (imipenem, meropenem and doripenem) are considered the agents of choice for A. baumannii infections. The presence of resistance to these agents constrains therapeutic ...